Zhejiang Shapuaisi Pharmaceutical (603168.SH) has obtained the approval notice for the supplementary application of Levofloxacin eye drops.

Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that recently, the company has received the "Supplementary Drug Application Approval Notice" for Levofloxacin Eye Drops issued by the National Medical Products Administration (NMPA) (Notice No.: 2025B01972). After review, it was found that the application for this product meets the relevant requirements for drug registration, and the supplement application for the research and control strategy of nitrosamine impurities in this product has been approved. The company's receipt of the "Supplementary Drug Application Approval Notice" for Levofloxacin Eye Drops this time has improved the safety information of this drug, which will contribute to its safe, effective, and rational use, and will enhance the market competitiveness of this product.